Lakeside Holding Acquires Hupan Pharmaceutical, Expanding Into China's Medical Logistics Sector

12 November 2024 | Tuesday | News


The $0.6 million acquisition of Hupan Pharmaceutical marks Lakeside's entry into China's pharmaceutical supply chain, adding an estimated $7 million in annual revenue and bolstering its capabilities in drug and medical device distribution across Hubei.
Image Source : Public Domain

Image Source : Public Domain

Lakeside Holding, a U.S.-based integrated cross-border supply chain solution provider with a strategic focus on the Asian market operating under the brand American Bear Logistics (ABL), is pleased to announce that through its wholly-owned subsidiary Sichuan Hupan Jincheng Enterprise Management Co., Ltd. ("Sichuan Hupan"), has entered into an equity transfer agreement to acquire Hupan Pharmaceutical (Hubei) Co., Ltd. ("Hupan Pharmaceutical"), gaining entry into the medical logistics sector. The acquisition, valued at RMB 4.0 million (US$0.6 million), is anticipated to deliver approximately US$7 million of annual revenues to Lakeside.

Founded in May 2024 and headquartered in Wuhan, Hupan Pharmaceutical is a comprehensive pharmaceutical distribution and supply chain service provider with verticals in brand promotion and healthcare technology support. Hupan Pharmaceutical is licensed for drug wholesale, retail, and third-class medical device distribution in China, with recent expansion to include refrigerated and frozen pharmaceuticals, peptide hormones, and other critical medications.

Hupan Pharmaceutical has partnerships with leading pharmaceutical manufacturers, regional healthcare institutions, and 15 major hospitals in Wuhan, including the Sinopharm Group Hubei Co., Ltd. The Sinopharm Group Hubei Co., Ltd. is the subsidiary of Sinopharm Group Co., Ltd.(Sinopharm Holding). Sinopharm Holding a top player in China's pharmaceutical industry, ranked 24th in the 2022 Fortune China 500 and first among pharmaceutical companies. It is recognized as a "2022 National Demonstration Enterprise for Supply Chain Innovation and Application" and among the top 100 most valuable Chinese brands.With an MSCI ESG rating of A, Sinopharm Holding is an industry leader in corporate responsibility and supply chain stability.

Known for its extensive clinical supply expertise in oncology, antibiotics, large-volume infusions, and aesthetic medicine, Hupan Pharmaceutical is well-positioned to meet the needs of a broad range of healthcare institutions across Hubei.

"The acquisition of Hupan Pharmaceutical provides Lakeside with an important foothold into the lucrative medical logistics trade," said Henry Liu, Chairman & CEO of Lakeside. "With American Bear Logistics and now Hupan Pharmaceutical, Lakeside is positioned with two highly specialized companies, each supported by experienced teams, advanced technology, and a solid foundation of customer trust. This acquisition enables us to bring top-tier logistics and supply chain solutions to the pharmaceutical sector in China, expanding our reach and capabilities across critical and emerging markets."

News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close